In its November 5, 2025 Q3 report, Novo Nordisk stated that the impact of compounded semaglutide is now materially lower than assumed three months ago and that the company sees a clear path to the copycat market becoming negligible in 2026
VY has nothing to disclose
Agarwal A, Dadge SD, Garg R, Chauhan D, Katekar R, Maity D, et al
Cystathionine-beta-synthase inhibition for colon cancer: enhancement of the efficacy of aminooxyacetic acid via the prodrug approach
U-100 Demonstration Pen U-200 Demonstration Pen Patient Website works and how to start taking it, plus support options and ways to save
Because alpha-lipoic acid has other beneficial effects on overall cardiovascular and diabetes risk, this makes it a good option